Groton, CT, United States of America

Roberto Colon-Cruz


Average Co-Inventor Count = 3.0

ph-index = 1

Forward Citations = 23(Granted Patents)


Company Filing History:


Years Active: 2004-2006

Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Roberto Colon-Cruz

Introduction

Roberto Colon-Cruz is a notable inventor based in Groton, CT (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds with neuroleptic activity and chemokine receptor antagonists. With a total of 2 patents to his name, Colon-Cruz continues to impact the medical community through his innovative work.

Latest Patents

Colon-Cruz's latest patents include groundbreaking research on acyl derivatives of 5-(2-(4-(1,2 benzisothiazole-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one, which have neuroleptic activity. This patent outlines a process for preparing acyl derivatives as prodrugs and their use as antipsychotic medications. Additionally, he has developed modulators of chemokine receptor activity, specifically targeting CCR2 and CCR3 receptors. These compounds are designed to treat or prevent diseases associated with monocyte, lymphocyte, or leucocyte accumulation.

Career Highlights

Roberto Colon-Cruz is currently employed at Pfizer Corporation, where he applies his expertise in pharmaceutical research and development. His work has been instrumental in advancing therapeutic options for various medical conditions.

Collaborations

Throughout his career, Colon-Cruz has collaborated with talented professionals, including Mary Theresa Didiuk and Erin M Duffy. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.

Conclusion

Roberto Colon-Cruz exemplifies the spirit of innovation in the pharmaceutical industry. His contributions through patents and collaborations continue to pave the way for advancements in medical treatments.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…